Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162139 | 1.00 | LMNA (0.48) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL14691171 | 1.00 | LMNA (0.48) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL571797 | 1.00 | LMNA (0.48) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL28707494 | 0.85 | LMNA (0.52) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL12180786 | 0.85 | LMNA (0.49) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL27486731 | 0.85 | LMNA (0.49) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL7139715 | 0.85 | SRC (0.47) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL8070685 | 0.85 | SRC (0.47) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL8108955 | 0.83 | LMNA (0.67) | LMNAHPGDTP53HDAC1 | |
| SCHEMBL530337 | 0.83 | LMNA (0.67) | LMNAHPGDTP53HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2337561-A1 | USE OF TOCOTRIENOL COMPOSITION FOR THE PREVENTION OF CANCER | Davos Life Science Pte. Ltd. (SG) | 2011-06-29 | — | — | EP | claimed |
| WO-2010047663-A1 | USE OF TOCOTRIENOL COMPOSITION FOR THE PREVENTION OF CANCER | DAVOS LIFE SCIENCE PTE. LTD. (SG) | 2010-04-29 | — | — | WO | claimed |
| EP-4706770-A2 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| EP-4265300-B1 | COMPOSITION COMPRISING A 17 A-HYDROXYLASE/C17,20 LYASE (CYP17A1) INHIBITOR AND AN AKT INHIBITOR | NOVARTIS AG (CH) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025235719-A1 | DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4397376-A2 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3468953-B1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-05-22 | — | — | EP | disclosed |
| EP-4159217-B1 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | NOVARTIS AG (CH) | 2024-05-22 | — | — | EP | disclosed |
| EP-4342473-A2 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-03-27 | — | — | EP | disclosed |
| EP-4159205-B1 | NOVEL PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| EP-4159204-B1 | NOVEL PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| US-7332617-B2 | Process for the preparation of docetaxel trihydrate | SHANGHAI DESANO CHEMICAL PHARMACEUTICAL CO., LTD. (CN) | 2008-02-19 | — | — | US | disclosed |
| US-20070197538-A1 | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-08-23 | — | — | US | disclosed |
| WO-2006128740-A2 | ANTI-VASCULAR METHODS AND THERAPIES EMPLOYING LYSYL OXIDASE INHIBITORS | CENTELION (FR) | 2006-12-07 | — | — | WO | disclosed |
| US-20060217436-A1 | Process for the preparation of docetaxel trihydrate | SHANGHAI DESANO CHEMICAL PHARMACEUTICAL CO., LTD (CN) | 2006-09-28 | — | — | US | disclosed |
| EP-1694660-A1 | PROCESS FOR THE PREPARATION OF ANHYDROUS AND HYDRATED ACTIVE PHARMACEUTICAL INGREDIENTS (APIS); STABLE PHARMACEUTICAL COMPOSITIONS PREPARED FROM THE SAME AND USES OF SAID COMPOSITIONS | Quiral Quimica Do Brasil (BR) | 2006-08-30 | — | — | EP | disclosed |
| EP-1687642-A2 | ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS | CENTELION (FR) | 2006-08-09 | — | — | EP | disclosed |
| EP-1623982-A1 | THE PROCESS FOR THE PREPARATION OF DOCETAXEL TRIHYDRATE | Shanghai Desano Chemical Pharmaceutical CO., Ltd. (CN) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005061474-A1 | PROCESS FOR THE PREPARATION OF ANHYDROUS AND HYDRATED ACTIVE PHARMACEUTICAL INGREDIENTS (APIS); STABLE PHARMACEUTICAL COMPOSITIONS PREPARED FROM THE SAME AND USES OF SAID COMPOSITIONS | QUIRAL QUÍMICA DO BRASIL (BR) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005038465-A2 | ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS | CENTELION (FR) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197538-A1 | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors | MCL1, ABL1, TIE1 | LMNA 2763/4885MAPK1 157/4885KEAP1 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.